| Year |
Citation |
Score |
| 2020 |
Evgin L, Huff AL, Wongthida P, Thompson J, Kottke T, Tonne J, Schuelke M, Ayasoufi K, Driscoll CB, Shim KG, Reynolds P, Monie DD, Johnson AJ, Coffey M, Young SL, ... ... Sampson J, et al. Oncolytic virus-derived type I interferon restricts CAR T cell therapy. Nature Communications. 11: 3187. PMID 32581235 DOI: 10.1038/S41467-020-17011-Z |
0.317 |
|
| 2020 |
Reardon DA, Brandes AA, Omuro A, Mulholland P, Lim M, Wick A, Baehring J, Ahluwalia MS, Roth P, Bähr O, Phuphanich S, Sepulveda JM, De Souza P, Sahebjam S, Carleton M, ... ... Sampson J, et al. Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: The CheckMate 143 Phase 3 Randomized Clinical Trial. Jama Oncology. PMID 32437507 DOI: 10.1001/Jamaoncol.2020.1024 |
0.344 |
|
| 2019 |
Evgin L, Huff AL, Wongthida P, Thompson J, Kottke T, Sampson J, Perez LS, Vile R. Abstract A029: Unexpected antagonism between oncolytic virus derived type I interferon and EGFRvIII CAR T-cells Cancer Immunology Research. 7. DOI: 10.1158/2326-6074.Cricimteatiaacr18-A029 |
0.318 |
|
| 2019 |
Landi D, Archer G, Driscoll T, Herndon J, Sampson J, Ashley D. Pdct-10. Feasibility Of Leukapheresis For Harvesting Monocytes And Generating Autologous Dendritic Cell Vaccines In Children With Malignant Brain Tumors Neuro-Oncology. 21. DOI: 10.1093/Neuonc/Noz175.772 |
0.328 |
|
| 2019 |
Schaller T, Foster M, Spasojevic I, Gedeon P, Sanchez-Perez L, Sampson J. EXTH-09. FIRST-IN-HUMAN DOSING CONSIDERATIONS OF A BISPECIFIC ANTIBODY FOR TREATING GLIOBLASTOMA Neuro-Oncology. 21: vi84-vi84. DOI: 10.1093/Neuonc/Noz175.343 |
0.37 |
|
| 2019 |
Weller M, Reardon D, Brandes A, Sampson J, Mulholland P, Wick A, Baehring J, Ahluwalia M, Roth P, Bähr O, Phuphanich S, Sepulveda J, Souza Pd, Sahebjam S, Potter V, et al. Atim-47. Nivolumab Vs Bevacizumab In Patients With Recurrent Glioblastoma: Exploratory Analysis Of Mgmt Methylation Status And Baseline Corticosteroid Use Neuro-Oncology. 21. DOI: 10.1093/Neuonc/Noz175.045 |
0.313 |
|
| 2019 |
Peters K, Congdon K, Archer G, Woodring S, Jaggers D, Lipp E, Healy P, Herndon J, Soher B, Vlahovic G, Johnson M, Randazzo D, Desjardins A, Friedman H, Friedman A, ... Sampson J, et al. ATIM-31. SAFETY OF TUMOR-SPECIFIC PEPTIDE VACCINE TARGETING ISOCITRATE DEHYDROGENASE 1 MUTATION IN RECURRENT RESECTABLE LOW GRADE GLIOMA PATIENTS Neuro-Oncology. 21: vi8-vi8. DOI: 10.1093/Neuonc/Noz175.030 |
0.393 |
|
| 2019 |
Gromeier M, Brown M, Beuabier N, Yan H, He Y, Zhang G, Desjardins A, Herndon J, Bolognesi D, Friedman A, Friedman H, McSherry F, Lin X, Wei Z, Nair S, ... Sampson J, et al. ATIM-27. TUMOR MUTATIONAL BURDEN PREDICTS RESPONSE TO ONCOLYTIC POLIO/RHINOVIRUS RECOMBINANT (PVSRIPO) IN MALIGNANT GLIOMA PATIENTS: ASSESSMENT OF TRANSCRIPTIONAL AND IMMUNOLOGICAL CORRELATES Neuro-Oncology. 21: vi7-vi7. DOI: 10.1093/Neuonc/Noz175.026 |
0.417 |
|
| 2019 |
Desjardins A, Randazzo D, Chandramohan V, Peters K, Johnson M, Threatt S, Bullock C, Jackman J, Healy P, Lipp E, Sampson J, Friedman A, Friedman H, Ashley D, Bigner D. ATIM-24. DOSE FINDING AND DOSE EXPANSION TRIAL OF D2C7 IMMUNOTOXIN (D2C7-IT) ADMINISTERED INTRATUMORALLY VIA CONVECTION-ENHANCED DELIVERY (CED) FOR RECURRENT MALIGNANT GLIOMA (MG) Neuro-Oncology. 21: vi6-vi6. DOI: 10.1093/Neuonc/Noz175.023 |
0.374 |
|
| 2018 |
Batich K, Ashley D, Archer G, Sanchez-Perez L, Norberg P, Congdon K, Herndon J, McSherry F, Gemberling S, Hesler R, Jaggers D, Van R, Parker J, Peters K, Desjardins A, ... Sampson J, et al. RBTT-02. ENHANCING VACCINE RESPONSES WITH DOSE-INTENSIFIED TEMOZOLOMIDE IN GLIOBLASTOMA: INITIATION OF THE I-ATTAC TRIAL Neuro-Oncology. 20: vi234-vi234. DOI: 10.1093/Neuonc/Noy148.972 |
0.323 |
|
| 2018 |
Desjardins A, Randazzo D, Chandramohan V, Peters K, Johnson M, Thomas L, Threatt S, Bullock C, Herndon J, Boulton S, Healy P, Lipp E, Sampson J, Friedman A, Friedman H, et al. ATIM-36. DOSE ESCALATION TRIAL OF D2C7 IMMUNOTOXIN (D2C7-IT) ADMINISTERED INTRATUMORALLY VIA CONVECTION-ENHANCED DELIVERY (CED) FOR RECURRENT MALIGNANT GLIOMA (MG) Neuro-Oncology. 20: vi9-vi9. DOI: 10.1093/Neuonc/Noy148.031 |
0.339 |
|
| 2018 |
Gururangan S, Grant G, Driscoll T, Archer G, Herndon J, Friedman H, Kurtzberg J, Bigner D, Sampson J, Mitchell D. IMMU-27. Re-MATCH PROTOCOL: PHASE I STUDY OF AUTOLOGOUS TUMOR SPECIFIC LYMPHOCYTE TRANSFER (ALT) + DC VACCINE (DCV) DURING RECOVERY FROM MYELOABLATIVE CHEMOTHERAPY (MAC) AND AUTOLOGOUS STEM CELL RESCUE (HDC + ASCR) OR NON-MYELOABLATIVE CHEMOTHERAPY (NMAC) IN PATIENTS WITH RECURRENT CENTRAL PNETs (r-PNET) Neuro-Oncology. 20. DOI: 10.1093/Neuonc/Noy059.343 |
0.39 |
|
| 2018 |
Landi D, Thompson E, Herndon J, Sampson J, Ashley D. IMMU-23. CMV pp65 RNA-PULSED DENDRITIC CELL VACCINES FOR PEDIATRIC GLIOBLASTOMA AND MEDULLOBLASTOMA: A PHASE I TRIAL Neuro-Oncology. 20. DOI: 10.1093/Neuonc/Noy059.339 |
0.302 |
|
| 2018 |
Schuelke M, Evgin L, Wongthida P, Thompson J, Kottke T, Sanchez-Perez L, Sampson J, Vile R. IMMU-12. T-CELL THERAPIES DEMONSTRATE EFFICACY WITHOUT TOXICITY IN IMMUNOCOMPETENT MODELS OF BRAINSTEM TUMORS Neuro-Oncology. 20: i101-i101. DOI: 10.1093/Neuonc/Noy059.328 |
0.354 |
|
| 2018 |
Bexon MF, Achrol A, Bankiewicz K, Brenner A, Butowski N, Kesari S, Merchant F, Merchant R, Randazzo D, Vogelbaum M, Zabek M, Sampson J. Understanding biological activity, tumor response and pseudoprogression in a phase-IIb study of MDNA55 in adults with recurrent or progressive glioblastoma (GB). Annals of Oncology. 29. DOI: 10.1093/Annonc/Mdy273.368 |
0.339 |
|
| 2017 |
Reardon DA, Omuro A, Brandes AA, Rieger J, Wick A, Sepulveda J, Phuphanich S, Souza Pd, Ahluwalia MS, Lim M, Vlahovic G, Sampson J. OS10.3 Randomized Phase 3 Study Evaluating the Efficacy and Safety of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: CheckMate 143 Neuro-Oncology. 19. DOI: 10.1093/Neuonc/Nox036.071 |
0.357 |
|
| 2017 |
Omuro A, Vlahovic G, Baehring J, Butowski N, Reardon D, Cloughesy T, Sahebjam S, Lim M, Zwirtes R, Sampson J. OS07.3 Nivolumab in Combination With Radiotherapy With or Without Temozolomide in Patients With Newly Diagnosed Glioblastoma: Updated Results From CheckMate 143 Neuro-Oncology. 19: iii13-iii13. DOI: 10.1093/Neuonc/Nox036.044 |
0.37 |
|
| 2017 |
Wang C, Sun W, Kirkpatrick JP, Sampson J, Chang Z, Yin FF. Assessment of Concurrent Stereotactic Radiosurgery and Bevacizumab Treatment of Recurrent Malignant Gliomas Using Multiparametric MRI Imaging and Radiomics Analysis International Journal of Radiation Oncology Biology Physics. 99. DOI: 10.1016/J.Ijrobp.2017.06.2367 |
0.33 |
|
| 2016 |
Desjardins A, Randazzo D, Chandramohan V, Sampson J, Peters K, Vlahovic G, Threatt S, Herndon J, Boulton S, Lally-Goss D, Healy P, Lipp E, Friedman A, Friedman H, Bigner D. ATIM-18. PHASE I DOSE ESCALATION STUDY OF D2C7-IT ADMINISTERED INTRATUMORALLY VIA CONVECTION-ENHANCED DELIVERY (CED) FOR RECURRENT MALIGNANT GLIOMA (MG) Neuro-Oncology. 18: vi21-vi22. DOI: 10.1093/Neuonc/Now212.083 |
0.347 |
|
| 2016 |
Omuro A, Vlahovic G, Baehring J, Butowski NA, Reardon DA, Cloughesy T, Sahebjam S, Lim M, Strauss L, Latek R, Zwirtes R, Paliwal P, Harbison C, Sampson J. ATIM-16. NIVOLUMAB COMBINED WITH RADIOTHERAPY WITH OR WITHOUT TEMOZOLOMIDE IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA: RESULTS FROM PHASE 1 SAFETY COHORTS IN CHECKMATE 143 Neuro-Oncology. 18: vi21-vi21. DOI: 10.1093/Neuonc/Now212.081 |
0.353 |
|
| 2015 |
Flores C, Pham C, Snyder D, Yang S, Sanchez-Perez L, Sayour E, Cui X, Kemeny H, Friedman H, Bigner DD, Sampson J, Mitchell DA. Novel role of hematopoietic stem cells in immunologic rejection of malignant gliomas. Oncoimmunology. 4: e994374. PMID 25949916 DOI: 10.4161/2162402X.2014.994374 |
0.37 |
|
| 2015 |
Boyle J, McSherry F, Herndon J, Desjardins A, Sampson J, Peters K, Chino J, Allen K, Cabrera A, Kim G, Friedman H, Kirkpatrick J. Rtrb-04Stereotactic Radiosurgery For Recurrent High-Grade Gliomas: Patient Selection And The Role Of Bevacizumab Neuro-Oncology. 17. DOI: 10.1093/Neuonc/Nov231.04 |
0.371 |
|
| 2015 |
Okada H, Weller M, Huang R, Finocchiaro G, Gilbert M, Wick W, Ellingson B, Hashimoto N, Pollack I, Brandes A, Franceschi E, Herold-Mende C, Nayak L, Panigrahy A, Pope W, ... Sampson J, et al. NIMG-56IMMUNOTHERAPY RESPONSE ASSESSMENT IN NEURO-ONCOLOGY (iRANO): A REPORT OF THE RANO WORKING GROUP Neuro-Oncology. 17. DOI: 10.1093/Neuonc/Nov225.56 |
0.403 |
|
| 2015 |
Omuro A, Baehring J, Sahebjam S, Vlahovic G, Voloschin A, Young R, Hayes W, Latek R, Coric V, Cloughesy T, Lim M, Sampson J, Reardon DA. NIMG-18EVALUATING TUMOR PROGRESSION AND IMMUNOLOGIC REACTIONS DURING IMMUNOTHERAPY: NEUROIMAGING OBSERVATIONS FROM A MULTICENTER STUDY OF NIVOLUMAB MONOTHERAPY AND NIVOLUMAB IN COMBINATION WITH IPILIMUMAB IN RECURRENT GLIOBLASTOMA (CHECKMATE-143) Neuro-Oncology. 17: v157.1-v157. DOI: 10.1093/Neuonc/Nov225.18 |
0.379 |
|
| 2015 |
Ramkissoon S, Sampson J, Vlahovic G, Sahebjam S, Omuro A, Baehring J, Latek R, Vandeloise E, Coric V, Cloughesy T, Lim M, Reardon D, Ligon K. NIMG-17CENTRAL NEUROPATHOLOGY REVIEW TO ASSIST IN THE EVALUATION OF IMMUNE-RELATED TREATMENT CHANGES VERSUS DISEASE PROGRESSION IN CHECKMATE-143 Neuro-Oncology. 17: v156.4-v157. DOI: 10.1093/Neuonc/Nov225.17 |
0.409 |
|
| 2015 |
Sahebjam S, Omuro A, Baehring J, Sampson J, Vlahovic G, Voloschin A, Hayes W, Latek R, Coric V, Cloughesy T, Lim M, Reardon DA. NIMG-16PSEUDOPROGRESSION AND IMMUNOTHERAPY IN GLIOBLASTOMA: A CASE SERIES FROM COHORT 1 OF CHECKMATE-143 (NCT02017717) Neuro-Oncology. 17: v156.3-v156. DOI: 10.1093/Neuonc/Nov225.16 |
0.382 |
|
| 2015 |
Sampson J, Omuro A, Vlahovic G, Sahebjam S, Baehring J, Hafler DA, Voloschin A, Simon J, Latek R, Coric V, Cloughesy T, Lim M, Reardon D. IMCT-03SAFETY AND ACTIVITY OF NIVOLUMAB MONOTHERAPY AND NIVOLUMAB IN COMBINATION WITH IPILIMUMAB IN RECURRENT GLIOBLASTOMA: UPDATED RESULTS FROM CHECKMATE-143 Neuro-Oncology. 17: v107.3-v107. DOI: 10.1093/Neuonc/Nov218.03 |
0.435 |
|
| 2015 |
Pham C, Flores C, Yang C, Sayour E, Pei Y, Moore C, McLendon R, Huang J, Sampson J, Wechsler-Reya R, Mitchell D. IMPS-25DIFFERENTIAL TUMOR MICROENVIRONMENTS AND RESPONSE TO IMMUNE CHECKPOINT BLOCKADE IN MOLECULAR SUBTYPES OF MURINE MEDULLOBLASTOMA Neuro-Oncology. 17: v118.3-v118. DOI: 10.1093/Neuonc/Nov217.24 |
0.346 |
|
| 2015 |
Lowther DE, Weinhold K, Reap E, Vlahovic G, Omuro A, Sahebjam S, Baehring J, Voloschin A, Cloughesy T, Lim M, Coric V, Latek R, Simon J, Lerner B, Raddassi K, ... Sampson J, et al. CBM-06IMMUNE BIOMARKER RESULTS FROM A TRIAL OF NIVOLUMAB ± IPILIMUMAB IN PATIENTS WITH RECURRENT GLIOBLASTOMA: CHECKMATE-143 Neuro-Oncology. 17: v70.2-v70. DOI: 10.1093/Neuonc/Nov211.06 |
0.42 |
|
| 2015 |
Weant M, Dunn-Pirio A, Peters K, Vlahovic G, Randazzo D, Herndon J, Healy P, Threatt S, Sampson J, Friedman A, Friedman H, Desjardins A. Atct-13Bevacizumab, Radiation Therapy (Rt) And Temozolomide Followed By Bevacizumab And Temozolomide With Continuation Of Bevacizumab Beyond Progression: A Phase Ii Trial Neuro-Oncology. 17. DOI: 10.1093/Neuonc/Nov206.13 |
0.382 |
|
| 2014 |
Mowery Y, Wright A, Desjardins A, Peters K, Ranjan T, Vlahovic G, Friedman H, Zomorodi A, Kaylie D, Adogwa O, Nimjee S, Sperduto W, Chagoya G, Fatemi P, McLendon R, ... Sampson J, et al. MS-19 * LONG-TERM OUTCOMES FOR PATIENTS WITH INTRACRANIAL MENINGIOMAS: A SINGLE-INSTITUTION RETROSPECTIVE ANALYSIS Neuro-Oncology. 16: v130-v131. DOI: 10.1093/Neuonc/Nou260.18 |
0.391 |
|
| 2014 |
Flores C, Pham C, Snyder D, Yang S, Sanchez-Perez L, Sayour E, Cui X, Kemeny H, Friedman H, Bigner D, Sampson J, Mitchell D. IT-10 * SYNERGISTIC CELLULAR INTERACTIONS IN ADOPTIVE IMMUNOTHERAPY LEADS TO IMMUNOLOGIC REJECTION OF MALIGNANT GLIOMA Neuro-Oncology. 16: v111-v111. DOI: 10.1093/Neuonc/Nou258.8 |
0.391 |
|
| 2014 |
Vlahovic G, Archer G, Lally-Goss D, Reap E, Batich K, Desjardins A, Peters K, Ranjan T, Healy P, Herndon J, Friedman A, Friedman H, Bigner D, Sampson J. IT-34 * PILOT STUDY OF COMBINATION OF ANTITUMOR IMMUNOTHERAPY TARGETED AGAINST CYTOMEGALOVIRUS (CMV) PLUS REGULATORY T-CELL INHIBITION IN PATIENTS WITH NEWLY-DIAGNOSED GLIOBLASTOMA MULTIFORME (GBM) Neuro-Oncology. 16: v117-v117. DOI: 10.1093/Neuonc/Nou258.32 |
0.396 |
|
| 2014 |
Reardon D, Schuster J, Tran D, Fink K, Nabors L, Li G, Lukas R, Desjardins A, Ashby L, Duic JP, Aneiro L, Hawthorne T, Green J, Yellin M, Davis T, Sampson J, et al. IT-30ReACT: A PHASE II STUDY OF RINDOPEPIMUT VACCINE (CDX-110) PLUS BEVACIZUMAB IN RELAPSED GLIOBLASTOMA Neuro-Oncology. 16. DOI: 10.1093/Neuonc/Nou258.28 |
0.412 |
|
| 2014 |
Kirkpatrick J, Wang Z, Sampson J, McSherry F, Herndon J, Allen K, Duffy E, Chang Z, Hoang J, Kelsey C, Yoo D, Cabrera A, Yin F. Bm-17Final Results Of A Randomized Trial To Identify The Optimal Planning Target Volume In Image-Guided Stereotactic Radiosurgery Of Brain Metastases Neuro-Oncology. 16. DOI: 10.1093/Neuonc/Nou240.17 |
0.353 |
|
| 2014 |
Ghiaseddin A, Dunn-Pirio A, Peters K, Vlahovic G, Herndon J, Threatt S, Sampson J, Friedman A, Friedman H, Desjardins A. At-22Phase Ii Trial Of Bevacizumab, Radiation Therapy (Rt) And Temozolomide Followed By Bevacizumab And Temozolomide With Continuation Of Bevacizumab Beyond Progression Neuro-Oncology. 16. DOI: 10.1093/Neuonc/Nou237.22 |
0.389 |
|
| 2014 |
Desjardins A, Sampson J, Peters K, Vlahovic G, Threatt S, Herndon J, Boulton S, Lally-Goss D, McSherry F, Lipp E, Friedman A, Friedman H, Bigner D, Gromeier M. AT-21 * FINAL RESULTS OF A PHASE 1 TRIAL OF AN ONCOLYTIC POLIO/RHINOVIRUS RECOMBINANT (PVSRIPO) AGAINST RECURRENT GLIOBLASTOMA (GBM) Neuro-Oncology. 16: v13-v13. DOI: 10.1093/Neuonc/Nou237.21 |
0.386 |
|
| 2014 |
Desjardins A, Herndon J, McSherry F, Ravelo A, Lipp E, Healy P, Peters K, Vlahovic G, Sampson J, Friedman A, Friedman H. At-20Single Institution Retrospective Review Of Performance Status And Corticosteroid Use In Newly Diagnosed Glioblastoma (Gbm) Patients (Pts) Treated On Bevacizumab (Bev) Neuro-Oncology. 16. DOI: 10.1093/Neuonc/Nou237.20 |
0.348 |
|
| 2014 |
Desjardins A, Herndon J, McSherry F, Ravelo A, Lipp E, Healy P, Boulton S, Peters K, Vlahovic G, Sampson J, Friedman A, Friedman H. At-19Single Institution Retrospective Comparison Of Glioblastoma (Gbm) Patients (Pts) Initiated On Bevacizumab (Bev) Before Versus After Recurrence In Clinical Practice Neuro-Oncology. 16. DOI: 10.1093/Neuonc/Nou237.19 |
0.311 |
|
| 2014 |
Gromeier M, Dobrikova E, Dobrikov M, Brown M, Bryant J, Threatt S, Boulton S, Carter K, Herndon J, Desjardins A, Friedman H, Sampson J, Friedman A, Bigner D. ONCOLYTIC POLIOVIRUS IMMUNOTHERAPY OF GLIOBLASTOMA Neuro-Oncology. 16: iii41-iii41. DOI: 10.1093/Neuonc/Nou208.69 |
0.349 |
|
| 2014 |
Sampson J, Mitchell DA, Batich KA, Snyder D, Xie W, Reap E, Cui X, Sanchez-Perez L, Archer GE, Nair SK, Gunn MD. RANDOMIZATION OF PATIENTS WITH GLIOBLASTOMA TO VACCINE SITE PRE-CONDITIONING WITH TETANUS-DIPHTHERIA TOXOID SYSTEMICALLY ENHANCES MIGRATION AND THERAPEUTIC EFFECT OF CYTOMEGALOVIRUS PP65-PULSED DENDRITIC CELL VACCINE IN A MIP-1α-DEPENDENT FASHION Neuro-Oncology. 16. DOI: 10.1093/Neuonc/Nou208.63 |
0.344 |
|
| 2013 |
Dannull J, Haley NR, Archer G, Nair S, Boczkowski D, Harper M, De Rosa N, Pickett N, Mosca PJ, Burchette J, Selim MA, Mitchell DA, Sampson J, Tyler DS, Pruitt SK. Melanoma immunotherapy using mature DCs expressing the constitutive proteasome. The Journal of Clinical Investigation. 123: 3135-45. PMID 23934126 DOI: 10.1172/Jci67544 |
0.343 |
|
| 2012 |
Vredenburgh JJ, Desjardins A, Kirkpatrick JP, Reardon DA, Peters KB, Herndon JE, Marcello J, Bailey L, Threatt S, Sampson J, Friedman A, Friedman HS. Addition of bevacizumab to standard radiation therapy and daily temozolomide is associated with minimal toxicity in newly diagnosed glioblastoma multiforme. International Journal of Radiation Oncology, Biology, Physics. 82: 58-66. PMID 21036490 DOI: 10.1016/J.Ijrobp.2010.08.058 |
0.321 |
|
| 2012 |
Dannull J, Haley NR, Archer G, Nair S, Rosa ND, Selim M, Tyler DS, Sampson J, Pruitt SK. Abstract 5373: Altering the composition of the proteasome of melanoma antigen RNA-transfected dendritic cells enhances vaccination-induced anti-melanoma immunity: results of a Phase I trial Cancer Research. 72: 5373-5373. DOI: 10.1158/1538-7445.Am2012-5373 |
0.346 |
|
| 2012 |
Lewis S, Vredenburgh J, Desjardins A, Peters K, Green S, Hood R, Yang Y, Sampson J, Wang Z, Kirkpatrick JP. Patterns of Failure as a Function of Clinical Target Volumes in Patients With GBM Treated With Radiation Therapy (RT), Temozolomide, and Bevacizumab International Journal of Radiation Oncology Biology Physics. 84. DOI: 10.1016/J.Ijrobp.2012.07.694 |
0.323 |
|
| 2012 |
Cuneo KC, Vredenburgh J, Desjardins A, Peters K, Sampson J, Allen K, Chang Z, Duffy E, Peterson B, Kirkpatrick JP. Impact of Concurrent and Adjuvant Bevacizumab on the Risk of Radiation Necrosis Following Radiosurgery for Recurrent Glioma International Journal of Radiation Oncology Biology Physics. 84. DOI: 10.1016/J.Ijrobp.2012.07.024 |
0.304 |
|
| 2011 |
Reardon DA, Desjardins A, Peters K, Gururangan S, Sampson J, Rich JN, McLendon R, Herndon JE, Marcello J, Threatt S, Friedman AH, Vredenburgh JJ, Friedman HS. Phase II study of metronomic chemotherapy with bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy. Journal of Neuro-Oncology. 103: 371-9. PMID 20853132 DOI: 10.1007/S11060-010-0403-6 |
0.442 |
|
| 2011 |
Cuneo KC, Cabrera AR, Sampson J, Allen K, Duffy E, Vredenburgh JJ, Peters KB, Chang Z, Desjardins A, Kirkpatrick JP. Concurrent bevacizumab and radiosurgery for recurrent malignant glioma: toxicity results from a prospective pilot study F1000research. 2. DOI: 10.7490/F1000Research.1089492.1 |
0.421 |
|
| 2011 |
Cuneo KC, Cabrera AR, Sampson J, Allen K, Duffy E, Vredenburgh JJ, Peters KB, Chang Z, Desjardins A, Kirkpatrick JP. Bevacizumab and Radiosurgery for Recurrent Malignant Glioma: Toxicity Results from a Prospective Pilot Study International Journal of Radiation Oncology Biology Physics. 81. DOI: 10.1016/J.Ijrobp.2011.06.330 |
0.382 |
|
| 2010 |
Kunwar S, Chang S, Westphal M, Vogelbaum M, Sampson J, Barnett G, Shaffrey M, Ram Z, Piepmeier J, Prados M, Croteau D, Pedain C, Leland P, Husain SR, Joshi BH, et al. Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent glioblastoma. Neuro-Oncology. 12: 871-81. PMID 20511192 DOI: 10.1093/Neuonc/Nop054 |
0.414 |
|
| 2010 |
Oh DS, Reardon DA, Prosnitz LR, Gockerman JP, Sampson J, Kirkpatrick JP. Low-dose Whole Brain Radiotherapy followed by Radiosurgery for Primary CNS Lymphoma Achieving Partial Response to Induction Chemotherapy International Journal of Radiation Oncology Biology Physics. 78. DOI: 10.1016/J.Ijrobp.2010.07.696 |
0.331 |
|
| 2008 |
Desjardins A, Reardon DA, Herndon JE, Marcello J, Quinn JA, Rich JN, Sathornsumetee S, Gururangan S, Sampson J, Bailey L, Bigner DD, Friedman AH, Friedman HS, Vredenburgh JJ. Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 7068-73. PMID 18981004 DOI: 10.1158/1078-0432.Ccr-08-0260 |
0.427 |
|
| 2008 |
Selznick LA, Shamji MF, Fecci P, Gromeier M, Friedman AH, Sampson J. Molecular strategies for the treatment of malignant glioma--genes, viruses, and vaccines. Neurosurgical Review. 31: 141-55; discussion 1. PMID 18259789 DOI: 10.1007/S10143-008-0121-0 |
0.393 |
|
| 2007 |
Vredenburgh JJ, Desjardins A, Herndon JE, Marcello J, Reardon DA, Quinn JA, Rich JN, Sathornsumetee S, Gururangan S, Sampson J, Wagner M, Bailey L, Bigner DD, Friedman AH, Friedman HS. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 25: 4722-9. PMID 17947719 DOI: 10.1200/Jco.2007.12.2440 |
0.415 |
|
| Show low-probability matches. |
_Sampson.jpg)